EdiGENE Corporation is an innovative biotech company dedicated to developing transformative therapeutics for unmet medical needs. Utilizing cutting-edge CRISPR gene editing and advanced protein engineering technologies, we aim to address diseases caused by genetic mutations that cannot be effectively treated or cured with current therapies. Our proprietary platforms, backed by strong intellectual property licensed from the University of Tokyo, enable us to target previously "undruggable" diseases and offer new solutions for patients worldwide.
Why CRISPR and Protein Engineering?
Many genetic diseases are caused by mutations that lead to malfunctioning proteins. CRISPR-Cas9 allows us to make precise edits to the DNA, correcting genetic mutations at their source. Protein engineering enables us to design custom proteins to replace or optimize defective ones. Together, these technologies offer the potential for curative therapies, rather than just symptom management.Transforming Healthcare: Targeting Undruggable Diseases Some diseases have long been considered “undruggable” due to complex genetic factors. With CRISPR, we can directly target and edit genes that drive conditions like cancer, autoimmune diseases, and neurodegenerative disorders. Protein engineering enhances this by designing therapies that specifically target and repair malfunctioning proteins.
Shaping the Future of Medicine
We believe that the combination of CRISPR and protein engineering will redefine how we treat genetic diseases. Our goal is to develop personalized medicine that targets the root causes of diseases, offering hope to patients with conditions previously thought to be incurable.
CRISPR market : Reaches $5.9 billion by 2027.
Approved CRISPR therapy: 50-80% efficacy in genetic diseases.
Clinical trials: Over 20,000 gene therapy trials.
Biotech growth: $2.4 trillion market by 2028
Revolutionizing Gene Therapy:
EdiGENE’s CRISPR & Protein Engineering Solutions
Let's Discover
hMPV !
HMPV and Cellular Metabolism
HMPV infection in airway epithelial cells is associated with alterations in key metabolic processes. Notably, changes in glycolysis and the hexosamine biosynthesis pathway have been observed. Upregulation of enzymes such as hexokinase 2 and pyruvate kinase M2, alongside a decrease in TCA cycle enzyme activity, suggests a shift toward anaerobic metabolism. These metabolic adjustments may play a significant role in the virus's impact on cell function and energy regulation.
For additional insights into how viral infections can affect metabolic pathways, you can explore further readings at this link